NCT00052689View on ClinicalTrials.gov

Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

October 31, 2007

Conditions
Duct Cell Adenocarcinoma of the PancreasStage IV Pancreatic Cancer
Interventions
DRUG

bortezomib

Given IV

DRUG

gemcitabine hydrochloride

Given IV

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00052689 - Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter